The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).
 
Shingo Matsumoto
Honoraria - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Oxford Oncology (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst); Takeda (Inst)
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takuma Yokoyama
No Relationships to Disclose
 
Haruyasu Murakami
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Nippon Boehringer Ingelheim; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Eiji Iwama
No Relationships to Disclose
 
Shunichi Sugawara
No Relationships to Disclose
 
Yuichiro Ohe
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche Pharma AG; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Novartis; Ono Pharmaceutical; Roche Pharma AG
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Koji Takeda
Honoraria - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Miyako Satouchi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Masato Shingyoji
No Relationships to Disclose
 
Daijiro Harada
No Relationships to Disclose
 
Takako Okuyama
No Relationships to Disclose
 
Norio Okamoto
No Relationships to Disclose
 
Takashi Kohno
No Relationships to Disclose
 
Koji Tsuta
No Relationships to Disclose
 
Genichiro Ishii
No Relationships to Disclose
 
Katsuya Tsuchihara
Honoraria - Chugai Pharma; Fujifilm; Integrated DNA Technologies; Taiho Pharmaceutical; Takeda
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Oxford Oncology (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)